2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay…�- The Lancet�…, 2019 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Save Cite Cited by 459 Related articles

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay, AA Khorana…�- The Lancet�…, 2019 - Elsevier
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite
[PDF] academia.edu

[PDF][PDF] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Fr�re, J Connors, C Ay, A Khorana… - 2019 - academia.edu
2019 international clinical practice guidelines for the treatment and prophylaxis of venous
thromboembolism in patients with can Page 1 HAL Id: hal-02394158 https://hal.sorbonne-universite.fr/hal-02394158�…
Cite

[CITATION][C] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay, AA Khorana…�- The Lancet�…, 2019 - cir.nii.ac.jp
Cite

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay…�- The Lancet�…, 2019 - pubmed.ncbi.nlm.nih.gov
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite
[PDF] thebloodproject.com

[PDF][PDF] 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay…�- Lancet�…, 2019 - thebloodproject.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay…�- THE LANCET�…, 2019 - irinsubria.uninsubria.it
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

D Farge, C Frere, JM Connors, C Ay…�- The Lancet�…, 2019 - thelancet.com
Venous thromboembolism (VTE) is the second leading cause of death in patients with
cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

D Farge, C Frere, JM Connors, C Ay, AA Khorana…�- The Lancet�…, 2019 - sonar.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

D Farge, C Frere, JM Connors, C Ay…�- The Lancet�…, 2019 - folia.unifr.ch
English Venous thromboembolism (VTE) is the second leading cause of death in patients
with cancer. These patients are at a high risk of VTE recurrence and bleeding during�…
Cite